Analysts See $-0.19 EPS for Affimed N.V. (AFMD)

March 18, 2018 - By Richard Conner

 Analysts See $ 0.19 EPS for Affimed N.V. (AFMD)

Analysts expect Affimed N.V. (NASDAQ:AFMD) to report $-0.19 EPS on March, 29.They anticipate $0.02 EPS change or 11.76 % from last quarter’s $-0.17 EPS. After having $-0.21 EPS previously, Affimed N.V.’s analysts see -9.52 % EPS growth. The stock decreased 4.44% or $0.1 during the last trading session, reaching $2.15. About 507,529 shares traded. Affimed N.V. (NASDAQ:AFMD) has declined 19.09% since March 18, 2017 and is downtrending. It has underperformed by 35.79% the S&P500.

Affimed N.V. (NASDAQ:AFMD) Ratings Coverage

Among 8 analysts covering Affimed Therapeutics (NASDAQ:AFMD), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Affimed Therapeutics had 17 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by Jefferies on Thursday, August 31 with “Hold”. The firm has “Hold” rating given on Thursday, May 19 by Jefferies. The stock of Affimed N.V. (NASDAQ:AFMD) earned “Hold” rating by Jefferies on Wednesday, September 9. The rating was maintained by Oppenheimer on Thursday, August 6 with “Outperform”. As per Friday, August 12, the company rating was downgraded by Leerink Swann. As per Tuesday, August 1, the company rating was maintained by Oppenheimer. The rating was downgraded by Leerink Swann to “Market Perform” on Thursday, May 19. Wells Fargo initiated Affimed N.V. (NASDAQ:AFMD) on Friday, December 4 with “Outperform” rating. Zacks upgraded the shares of AFMD in report on Monday, August 10 to “Sell” rating. The company was upgraded on Thursday, September 3 by Zacks.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. The company has market cap of $130.43 million. The Company’s lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. It currently has negative earnings. The company's product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.

More news for Affimed N.V. (NASDAQ:AFMD) were recently published by:, which released: “Affimed Announces Fourth Quarter and Year End 2017 Financial Results and …” on March 13, 2018.‘s article titled: “What’s Happening with These Biotech Stocks? — Aeterna Zentaris, Affimed …” and published on March 13, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.